Mechanism and treatment of motoneuron degeneration in ALS: What have SOD1 mutants told us?

被引:20
作者
Xu, ZS
机构
[1] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA
[3] Univ Massachusetts, Sch Med, Neurosci Program, Worcester, MA 01655 USA
来源
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS | 2000年 / 1卷 / 04期
关键词
neurodegenerative disease; superoxide dismutase; spinal cord; paralysis; degeneration;
D O I
10.1080/14660820050515052
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes motoneuron degeneration, skeletal muscle atrophy, paralysis and death. The identification of mutations in Cu,Zn superoxide dismutase (SOD1) as genetic cause of this disease has led to the creation of a number of in-vitro and in-vivo models. Experiments have been carried out in these model systems to address fundamental questions related to the disease: (1) what is the nature of toxicity of the mutated SOD1? (1) what are the cellular targets and pathways that lead to neuronal degeneration? (3) what makes motoneurons particularly vulnerable to the toxicity of the mutant enzyme? and (4) are there effective treatments for ALS based on current hypotheses regarding the disease mechanism? Current research on these questions is reviewed.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 131 条
[41]   Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis [J].
Gurney, ME ;
Fleck, TJ ;
Himes, CS ;
Hall, ED .
NEUROLOGY, 1998, 50 (01) :62-66
[42]   MOTOR-NEURON DEGENERATION IN MICE THAT EXPRESS A HUMAN CU,ZN SUPEROXIDE-DISMUTASE MUTATION [J].
GURNEY, ME ;
PU, HF ;
CHIU, AY ;
DALCANTO, MC ;
POLCHOW, CY ;
ALEXANDER, DD ;
CALIENDO, J ;
HENTATI, A ;
KWON, YW ;
DENG, HX ;
CHEN, WJ ;
ZHAI, P ;
SUFIT, RL ;
SIDDIQUE, T .
SCIENCE, 1994, 264 (5166) :1772-1775
[43]   Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familiar amyotrophic lateral sclerosis [J].
Gurney, ME ;
Cutting, FB ;
Zhai, P ;
Doble, A ;
Taylor, CP ;
Andrus, PK ;
Hall, ED .
ANNALS OF NEUROLOGY, 1996, 39 (02) :147-157
[44]   CORTICAL MOTOR-SENSORY HYPOMETABOLISM IN AMYOTROPHIC LATERAL SCLEROSIS - A PET STUDY [J].
HATAZAWA, J ;
BROOKS, RA ;
DALAKAS, MC ;
MANSI, L ;
DICHIRO, G .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1988, 12 (04) :630-636
[45]   CHANGES IN CA2+-BINDING PROTEINS IN HUMAN NEURODEGENERATIVE DISORDERS [J].
HEIZMANN, CW ;
BRAUN, K .
TRENDS IN NEUROSCIENCES, 1992, 15 (07) :259-264
[46]  
HEIZMANN CW, 1992, GEN PHYSIOL BIOPHYS, V11, P411
[47]   NEUROPROTECTIVE EFFECT OF BASIC FIBROBLAST GROWTH-FACTOR ON WOBBLER MOUSE MOTOR-NEURON DISEASE [J].
IKEDA, K ;
IWASAKI, Y ;
TAGAYA, N ;
SHIOJIMA, T ;
KOBAYASHI, T ;
KINOSHITA, M .
NEUROLOGICAL RESEARCH, 1995, 17 (06) :445-448
[48]   Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis [J].
Ikonomidou, C ;
Qin, YQ ;
Labruyere, J ;
Olney, JW .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (02) :211-224
[49]  
Ikonomidou C, 1996, CRIT REV NEUROBIOL, V10, P239
[50]   Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis [J].
Klivenyi, P ;
Ferrante, RJ ;
Matthews, RT ;
Bogdanov, MB ;
Klein, AM ;
Andreassen, OA ;
Mueller, G ;
Wermer, M ;
Kaddurah-Daouk, R ;
Beal, MF .
NATURE MEDICINE, 1999, 5 (03) :347-350